Erzotabart

作为一家成立后一年就获得IPO的抗体公司，Genmab早在二十多年前就创下了欧洲生物技术的纪录。现在，Genmab依靠以达雷妥尤单抗为主的若干全球销量TOP100重磅产品的销售分成，实现了每年数十亿美元的利润，并且这样的潜在明星单抗分子数目还在不断增加。目前已有8项使用了Genmab创新成果的疗法获得批准，约20项产品正在临床开发中。 2024年8月19日，AbbVie和Genmab共同宣布欧盟委员会（EC）已授予TEPKINLY®（epcoritamab）有条件上市授权，作为二线或多线治疗后复发或难治性（R/R）滤泡性淋巴瘤（FL）成年患者的单一疗法。这也是Tepkinly获得的第二次欧盟批准，作为适应症扩展。 1 重磅双特异性抗体疗法Tepkinly Tepkinly是一种皮下注射双特异性抗体，可与T细胞上的CD3受体和B细胞表面常见的CD20蛋白结合。这种作用机制使Tepkinly能够激活T细胞，诱导促炎细胞因子的释放，促进恶性B细胞的破坏。这种独特的作用机制使得Tepkinly在难治性滤泡性淋巴瘤患者中显示出显著的治疗潜力。该分子最初由Genmab开发，公司于2020年6月从AbbVie获得了7.5亿美元的预付款，总生物资金预计可达35亿美元，两家公司正在共同推进该疗法的商业化。 早在2022年2月，Tepkinly就首次获得欧盟批准，用于复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）的三线治疗。AbbVie表示，本次的适应症扩展使Tepkinly成为“第一个也是唯一一个”欧盟批准的皮下双特异性T细胞接合剂（BiTE），适用于复发或难治性滤泡性淋巴瘤（FL）或弥漫性大B细胞淋巴瘤。目前，Tepkinly在全球已经获得11项批准（药渡数据）。2024年上半年，TEPKINLY在Genmab获得特许权使用费收入的地区净销售额超1亿美元。 本次有条件上市授权得到了1/2期EPCORE®NHL-1临床试验数据的支持：这是一项开放标签、多队列、多中心、单臂试验，该研究包括对抗CD20单克隆抗体治疗和烷化剂均难治的患者（70%患有双重难治性疾病），对先前治疗难治的患者（82%），以及在开始任何首次全身治疗后两年内疾病进展的患者（52%）。 发表在《柳叶刀血液学》上的结果显示，接受Tepkinly治疗的患者（n=128）总体反应率（ORR）为83%，完全反应率（CR）为63%。中位随访16.2个月，中位反应持续时间为21.4个月。除了疗效显著外，Tepkinly的安全性数据也较为理想。在临床试验的优化队列中，没有报告高级别的细胞因子释放综合征（CRS）或免疫效应细胞相关神经毒性综合征（ICANS）的情况。相较于其他产品，Tepkinly疗效和安全性的双重优势有望为患者带来新的治疗希望。 弥漫性大B细胞淋巴瘤是我国人群最常见的淋巴瘤类型，目前R-CHOP治疗方案能显著延长各阶段患者的生存，但是部分一线高危患者和复发难治型患者仍面临着治疗效果差、成本高的生存困境。目前获批且常用的药物包括靶向CD79b的抗体药物偶联物优罗华®（维泊妥珠单抗）、双抗高罗华®（格菲妥单抗）。总的来说，弥漫性大B-细胞淋巴瘤批准上市的药物有超100个，临床阶段的药物有约250个；滤泡性淋巴瘤批准上市的药物有83个，临床阶段的药物有约150个。 2 Genmab半年财报亮眼 八月初，Genmab发布了2024年上半年财报，总收入为95.45亿丹麦克朗（约合14亿美元），与2023年上半年相比其收入增长了36%。25.42亿丹麦克朗（36%）的增长主要来自与杨森生物技术公司（Janssen）合作获得的DARZALEX®（daratumumab）特许权使用费，以及和诺华制药公司（Novartis Pharma AG）合作获得的KESIMPTA®（ofatumumab）特许权使用费，外加Epkinly净产品销售额的增加。2024年上半年总的特许权使用费收入为76.73亿丹麦克朗，而2023年上半年为58.86亿丹麦克朗。 此外，在2024年第二季度，Genmab达成了一系列重要里程碑，包括18亿美元收购普方生物（ProfoundBio），以及获得EPKINLY和Tivdak的监管批准，这进一步巩固了Genmab在差异化抗体疗法开发领域的地位。 3  License-out模式宗师级选手 License-out模式是指企业进行药物早期研发，然后将项目授权给其他药企做后期临床研发和上市销售，按里程碑模式获得各阶段临床成果以及商业化后的一定比例销售分成，收入可包含意向金、首付款、研发里程碑付款、销售里程碑付款、销售提成、终止履约金（分手费）等类目。 Genmab是欧洲创新药license-out的鼻祖之一，在公司成立那年便与Amgen就IL-15抗体（AMG714）达成合作。经过25年的发展，Genmab现在的代表性技术平台包括DuoBody®（双抗）、HexaBody®（六抗）、DuoHexaBody®和HexElect®，它们建立在天然抗体生物学的基础上，旨在利用人类免疫系统的力量抗击各种疾病。 DuoBody®平台能够稳定高效地大批量产生双特异性抗体，早在2012年7月，Genmab就与Janssen达成合作，利用DuoBody®平台开发双特异性抗体。HexaBody®平台能够创造强效疗法。在细胞表面靶向结合后，它诱导抗体六聚体的形成。这可以帮助产生强效的细胞毒性抗体，并用于触发诱导程序性细胞死亡的受体。这个技术可以将补体依赖性细胞毒性有限或缺失的抗体，转化为强效的细胞毒性抗体。HexaBody®平台也可以与其他平台联合使用。 Genmab通过几大技术平台进行差异化创新研发的策略为其多项license-out项目埋下伏笔。 其中，关键的几次项目合作包括： 2020年，Genmab与AbbVie签订合作协议，共同开发和商业化epcoritamab。两家公司在美国和日本共同承担商业化责任，AbbVie负责其他的全球商业化。Genmab从美国和日本以外的其他全球销售额中获得22%至26%的分层特许权使用费。 2019年，Genmab与Janssen签订了全球独家许可和期权协议以开发和商业化GEN3014。其主要适应症为多发性骨髓瘤。临床前试验中，GEN3014表现出增强的补体依赖性细胞毒性和强大的抗肿瘤活性。 Daratumumab由Janssen根据Genmab的全球独家许可进行开发和商业化。根据协议条款，Genmab将获得12%至20%的特许权使用费。 目前Genmab正在进行的5个3期临床的项目分别与Pfizer、BioNTech、AbbVie合作。 由合作伙伴销售的许可产品有三项，包括Janssen、Novartis、Horizon的合作产品。 4 结语 从Genmab产品的适应症来看，主要布局的是实体瘤、血液肿瘤，特别是那些难治的、易复发的肺癌和淋巴癌。这些癌种也是抗体类药物可以发挥独特作用的领域。Genmab许多药物都有多种临床阶段的适应症在研，也反映了使用免疫系统打击癌症这一策略的广泛适用性。 从license out模式到收购普方生物，Genmab开始寻找新的增长引擎。从另一方面来看，中国创新药企正在迅速崛起。 参考来源： 1. https://www.biospace.com/policy/abbvie-genmab-secure-european-label-expansion-for-tepkinly-in-follicular-lymphoma. August 20, 2024 2. Abbvie官网 3. Genmab官网 4. www.sec.gov 5. 药渡数据库 6. 景红梅：有用的新药好药都能纳入医保，是临床医生的朴素想法. https://www.eeo.com.cn/2024/0812/678891.shtml 2024-08-12 20:40 本文转载自Being科学/嘤嘤嘤 免责声明 本文系转载，仅做分享之用，不代表平台观点。图片、文章、字体等版权均属于原作者所有，如有侵权请告知，我们会及时处理。 ------------------------------ 「长按」二维码添加小达「进群」 与更多行业伙伴共探市场前沿资讯 艾美达医药咨询 艾美达（北京）医药信息咨询有限公司，成立于2014年4月，是一家专业的医药行业咨询服务提供商。公司致力于将产业政策研究与真实世界的数据挖掘深度结合，洞悉行业政策对市场的影响，通过专业的研究提供前瞻性的市场分析，为企业产品上市后的市场准入提供整体解决方案。

Media Release COPENHAGEN, Denmark; November 2, 2023 Eighteen total abstracts accepted for presentation and publication, including results from four clinical trials evaluating epcoritamab in multiple treatment settings and patient populations Oral presentations highlighting new findings from a clinical trial of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and a real-world analysis of patients with R/R large B-cell lymphoma (LBCL) will be featuredInitial data from trial of investigational cancer immunotherapy GEN3014 (HexaBody®-CD38) also acceptedGenmab to host virtual R&D Update and ASH Data Review on December 12 Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, across a variety of treatment settings and hematologic malignancies have been accepted for presentation and publication at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH), being held in San Diego, California, and virtually, December 9-12. The presentations will include two oral and 11 poster presentations highlighting data from several trials evaluating the safety and efficacy of epcoritamab as a monotherapy or in combination for the treatment of patients with various lymphoma subtypes, across lines of therapy including relapsed/refractory (R/R) and newly diagnosed patients. Additionally, results from a phase 1/2 trial evaluating GEN3014 (HexaBody-CD38), an investigational novel human CD38 monoclonal antibody, in patients with R/R multiple myeloma (MM), will be presented. All abstracts accepted for presentation have been published on the ASH website. “The breadth and depth of data accepted for presentation at this year’s American Society of Hematology meeting underline our dedication to comprehensive evaluation of our investigational medicines and reinforce our joint commitment with AbbVie to develop epcoritamab as a potential core therapy for B-cell malignancies,” said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. 2023 R&D Update and ASH Data ReviewOn Tuesday, December 12, at 11:00 AM EST (5:00 PM CET/4:00 PM GMT), Genmab will host its 2023 R&D Update and ASH Data Review. The event will be virtual and webcast live. Details, including the webcast link and registration will be available on www.genmab.com. This meeting is not an official program of the ASH Annual Meeting. Abstracts accepted for presentation at ASH: Epcoritamab (DuoBody-CD3xCD20) Abstract NumberAbstract TitleType of PresentationDate/Time of Presentation438Subcutaneous Epcoritamab Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma from EPCORE NHL-5. Avivi, I et al.OralSunday, December 10,9:30 - 11:00 AM PT1655Epcoritamab SC Monotherapy Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: Results from the EPCORE NHL-1 Dose Expansion Cohort. Linton KM et al. PosterSaturday, December 9, 5:30 - 7:30 PM PT1729CRS Mitigation Strategies: Preliminary Results from the DLBCL Optimization Arm A Cohort of EPCORE NHL-1. Vose J et al.PosterSaturday, December 9, 5:30 - 7:30 PM PT3053EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma. Falchi L et al. PosterSunday, December 10, 6:00 - 8:00 PM PT3092Epcoritamab SC + GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from EPCORE NHL-2. Brody J, et al.PosterSunday, December 10, 6:00 - 8:00 PM PT3135Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Li, T et al.PosterSunday, December 10, 6:00 - 8:00 PM PT4481Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Li, T et al.PosterMonday, December 11, 6:00 - 8:00 PM PT4457Subcutaneous Epcoritamab + R-mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose Anthracycline: Results from the EPCORE NHL-2 Phase 1/2 Trial. Vermaat JS et al.PosterMonday, December 11, 6:00 - 8:00 PM PT GEN3014 (HexaBody-CD38) Abstract NumberAbstract TitleType of PresentationDate/Time of Presentation4757GEN3014 (HexaBody®-CD38) in Anti-CD38 mAb–Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial. Grosicki S, et al.PosterMonday, December 11, 6:00 - 8:00 PM PT Outcomes Research Abstract NumberAbstract TitleType of PresentationDate/Time of Presentation309Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-cell Lymphoma (LBCL). Nastoupil L et al.OralSaturday, December 9, 4:00 - 5:30 PM PT1683Real-World Response Rates Across Lines of Therapy Among Patients With Relapsed/Refractory Follicular Lymphoma. Philips T et al. PosterSaturday, December 9, 5:30 - 7:30 PM PT1733Efficacy of Subcutaneous Epcoritamab vs Tisa-cel in R/R LBCL CAR T-naive and CAR T-eligible Patients: An Indirect Comparison. Salles G et al.PosterSaturday, December 9, 5:30 - 7:30 PM PT5089Cost-Effectiveness of Epcoritamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma After At Least Two Lines of Therapy in The United States. Qu et al.PosterMonday, December 11, 6:00 - 8:00 PM PT5158Patterns of Care and Resource Use Among Elderly Relapsed/Refractory Follicular Lymphoma Patients: US Medicare Claims Analysis. Chawla SB, et al.PosterMonday, December 11, 6:00 – 8:00 PM PTNAPractice Efficiency Associated with Epcoritamab for The Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma from an Institutional Perspective. Lei M et al.PublicationN/ANAEstimating the Number of Relapsed/Refractory Follicular Lymphoma Patients on Therapy in the United States. Johnston K et al.PublicationN/A Discovery Research Abstract NumberAbstract TitleType of PresentationDate/Time of PresentationNAAssessment of ultra-deep DIA mass spectrometry-based proteomics compared to flow cytometry and RNA-based methods for the discovery and validation of therapeutic targets in immune cells; Wah Au et al.PublicationN/ANAUnbiased Subtyping of AML: Unraveling Genomic and Transcriptomic Features for Precision Medicine and Targeted Therapies using Beat-AML and TCGA Data; Karagoz et alPublicationN/A The safety and efficacy of epcoritamab has not been established for these investigational uses. The safety and efficacy of HexaBody-CD38 has not been established. About Large B-cell Lymphoma (LBCL) LBCL is a fast-growing type of non-Hodgkin’s lymphoma (NHL), a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. There are an estimated 150,000 new LBCL cases each year globally.1,2 There are several subtypes of LBCL, including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). About Diffuse Large B-cell Lymphoma (DLBCL)DLBCL is the most common type of NHL worldwide, accounting for approximately 30 percent of all NHL cases and comprising an estimated 30,400 U.S. cases in 2022. DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.1,3 DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.1,4 About Follicular Lymphoma (FL)FL is typically an indolent (or slow growing) form of NHL that arises from B-lymphocytes.5 FL is the second most common form of NHL overall, accounting for 20-30 percent of all NHL cases, and represents 10-20 percent of all lymphomas in the western world.6,7 Although FL is an indolent lymphoma, it is considered incurable with conventional therapy.8,9 About EpcoritamabEpcoritamab (approved as EPKINLY™) is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. EPKINLY is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell mediated killing of CD20+ cells.10 EPKINLY (also known as TEPKINLY® in certain countries) has received regulatory approval in various indications and conditions in the U.S., Japan, the European Union, the United Kingdom and Canada. In the U.S., epcoritamab was added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a treatment option for diffuse large B-cell lymphoma (DLBCL). Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes three ongoing phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL (NCT: 04628494) compared to investigators choice chemotherapy, a phase 3 trial evaluating epcoritamab in combination with R-CHOP in adult participants with newly diagnosed DLBCL (NCT: 05578976), and a phase 3, open-label clinical trial evaluating epcoritamab in combination with rituximab and lenalidomide in patients with R/R FL (NCT: 05409066). Epcoritamab is not approved to treat newly diagnosed patients with DLBCL or FL. The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit clinicaltrials.gov for more information. EPKINLY™ (epcoritamab-bysp) U.S. IMPORTANT SAFETY INFORMATION Important Warnings—EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you may receive other medicines before receiving EPKINLY and you will also be given smaller doses of EPKINLY for the first 2 doses (called “step-up” dosing). Your first full dose of EPKINLY will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. Do not drive or use heavy machinery or do other dangerous activities if you have any symptoms that impair consciousness until your symptoms go away. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.Low blood cell counts are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Medication Guide, including Important Warnings. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO™) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab. Contact: David Freundel, Senior Director, Global Communications & Corporate AffairsT: +1 609 613 0504; E: dafr@genmab.com Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@genmab.comThis Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®,HexElect® and KYSO™. EPCORE™, EPKINLY™, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd. 1 Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. DOI: 10.1056/NEJMra2027612.2 Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146-171. DOI: 10.1016/j.critrevonc.2012.12.009.3 Kanas G, Ge W, Quek RGW, Keeven K, Nersesyan K, Arnason JE. Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. DOI: 10.1080/10428194.2021.1975188.4 Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. DOI: 10.1182/blood-2017-03-769620.5 What is Lymphoma. Lymphoma Research Foundation. https://lymphoma.org/aboutlymphoma/nhl/fl/. Accessed October 2023.6 Ma S. Risk factors of follicular lymphoma. Expert Opin Med Diagn. 2012;6:323-333. DOI: 10.1517/17530059.2012.686996.7 Luminari S, Bellei M, Biasoli I, Federico M. Follicular lymphoma—treatment and prognostic factors. Rev Bras Hematol Hemoter. 2012;34:54-59. DOI: 10.5581/1516-8484.20120015.8 Link BK, Day BM, Zhou X, et al. Second-Line and Subsequent Therapy and Outcomes for Follicular Lymphoma in the United States: Data From the Observational National LymphoCare Study. Br J Haematol. 2019;184(4):660-663. DOI: 10.1111/bjh.15149.9 Ren J, Asche CV, Shou Y, Galaznik. Economic Burden and Treatment Patterns for Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the USA. J Comp Eff Res. 2019;8(6):393-402. DOI: 10.2217/cer-2018-0094.10 Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625. Media Release no. 12CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark Attachment 021123_GENMAB 2023 ASH Curtain Raiser